Literature DB >> 16850120

Is paclitaxel/carboplatin really a useful regimen for ovarian cancer compared with platinum/doxorubicin/cyclophosphamide?

Toru Sugiyama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16850120     DOI： 10.1007/s10147-006-0572-7

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


× No keyword cloud information.
  9 in total

1.  A phase I/II study of carboplatin and paclitaxel in patients with epithelial ovarian cancer.

Authors:  Ritsu Yamamoto; Shinichiro Minobe; Masanori Kaneuchi; Noriaki Sakuragi; Seiichiro Fujimoto; Yoshiaki Ishizaki; Hiroka Domon; Hitoshi Hareyama; Chikara Sato; Takahumi Fujino; Isao Kawaguchi; Tatsumi Yamaguchi; Toshio Fujimoto; Ken Yoshiaki
Journal:  Jpn J Clin Oncol       Date:  2002-04       Impact factor: 3.019

2.  A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

Authors:  Andreas du Bois; Hans-Joachim Lück; Werner Meier; Hans-Peter Adams; Volker Möbus; Serban Costa; Thomas Bauknecht; Barbara Richter; Matthias Warm; Willibald Schröder; Sigrid Olbricht; Ulrike Nitz; Christian Jackisch; Günther Emons; Uwe Wagner; Walther Kuhn; Jacobus Pfisterer
Journal:  J Natl Cancer Inst       Date:  2003-09-03       Impact factor: 13.506

3.  Historical control study of paclitaxel-carboplatin (TJ) versus conventional platinum-based chemotherapy (CAP) for epithelial ovarian cancer.

Authors:  Reiko Numazaki; Etsuko Miyagi; Ryo Onose; Tsuneo Nakazawa; Ken Sugiura; Kunio Asukai; Hiroki Nakayama; Atsushi Miyamatsu; Naoyuki Okamoto; Fumiki Hirahara
Journal:  Int J Clin Oncol       Date:  2006-06       Impact factor: 3.402

4.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Authors:  M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

5.  A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer.

Authors:  Yuji Takei; Mitsuaki Suzuki; Michitaka Ohwada; Yasushi Saga; Takahiro Kohno; Shizuo Machida; Ikuo Sato
Journal:  Oncol Rep       Date:  2003 Jul-Aug       Impact factor: 3.906

6.  Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.

Authors: 
Journal:  Lancet       Date:  2002-08-17       Impact factor: 79.321

7.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Authors:  Robert F Ozols; Brian N Bundy; Benjamin E Greer; Jeffrey M Fowler; Daniel Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca Baergen
Journal:  J Clin Oncol       Date:  2003-07-14       Impact factor: 44.544

8.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Authors:  W P McGuire; W J Hoskins; M F Brady; P R Kucera; E E Partridge; K Y Look; D L Clarke-Pearson; M Davidson
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245

9.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

Authors:  Paul A Vasey; Gordon C Jayson; Alan Gordon; Hani Gabra; Rob Coleman; Ronnie Atkinson; David Parkin; James Paul; Andrea Hay; Stan B Kaye
Journal:  J Natl Cancer Inst       Date:  2004-11-17       Impact factor: 13.506
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.